• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design

tetano

Editor, Senior Moderator
Cell Host Microbe. 2017 Aug 9;22(2):193-206. doi: 10.1016/j.chom.2017.07.013.
[h=1]Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design.[/h] Crowe JE Jr[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Antibodies are the principal immune effectors that mediate protection against reinfection following viral infection or vaccination. Robust techniques for human mAb isolation have been developed in the last decade. The study of human mAbs isolated from subjects with prior immunity has become a mainstay for rational structure-based, next-generation vaccine development. The plethora of detailed molecular and genetic studies coupling the structure of antigen-antibody complexes with their antiviral function has begun to reveal common principles of critical interactions on which we can build better vaccines and therapeutic antibodies. This review outlines the approaches to isolating and studying human antiviral mAbs and discusses the common principles underlying the basis for their activity. This review also examines progress toward the goal of achieving a comprehensive understanding of the chemical and physical basis for molecular recognition of viral surface proteins in order to build predictive molecular models that can be used for vaccine design.
Copyright ? 2017. Published by Elsevier Inc.


[h=4]KEYWORDS:[/h] Ebola virus; Marburg virus; antibodies; dengue virus; human; influenza virus; monoclonal antibodies; neutralization

PMID: 28799905 DOI: 10.1016/j.chom.2017.07.013
 
Back
Top Bottom